Semler Scientific, Inc. Q1 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Financial Performance
  • Total Revenues: $15.9 million – a 13% decrease compared to Q1 2023.
  • Revenue Breakdown:
    • Fixed fee revenues: $7.1 million – down 24% YoY.
    • Variable fee revenues: $8 million – down 6% YoY.
    • Equipment/other revenues: $0.8 million – up 140% YoY.
  • Operating Expenses: $8.9 million – down 25% YoY, representing 56% of revenues vs. 66% in Q1 2023.
  • Pretax Net Income: $7.8 million, compared to $6.6 million in Q1 2023.
  • Net Income: $6.1 million
    • $0.88 per basic share and $0.78 per diluted share, up from $0.74 and $0.63 respectively in Q1 2023.
  • Cash Position: Record high of $62.9 million as of March 31, 2024.
Regulatory and Product Updates
  • Semler is pursuing an additional FDA 510(k) clearance for QuantaFlo to expand use into heart dysfunction detection.
  • Anticipated approval is expected in the second half of 2024.
  • While clearance is awaited, company continues focus on PAD diagnosis market.
Impact of CMS Changes

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good afternoon, and welcome to the Semler Scientific 2024 First Quarter Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. Before we begin, Semler Scientific needs to remind you that certain comments made during this call may constitute forward-looking statements and are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. These include statements regarding the expectations for expansion of the business and the development and marketing of additional products, including receipt and time of an additional 501(k) clearance for QuantaFlo and investment in emerging growth opportunities. Such forward-looking statements are subject to both known and unknown risks and uncertainties that could cause actual results to differ materially from such statements. Those risks and uncertainties are described in the press release and our SEC filings. The forward-looking statements made today are as of the date of this call, and the company does not undertake any obligation to update the forward-looking statements. If you do not have a copy of today's release, you may obtain one by visiting the Investor Relations page of the website, semlerscientific.com. Now I would like to introduce Douglas Murphy-Chutorian, CEO of Semler Scientific. Douglas Murphy-Chutorian: Afternoon, everybody. Thank you for joining us on our first quarter 2024 results call.

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional